Review





Similar Products

rabbit anti glast  (Alomone Labs)
94
Alomone Labs rabbit anti glast
Rabbit Anti Glast, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti glast/product/Alomone Labs
Average 94 stars, based on 1 article reviews
rabbit anti glast - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
anti glast 1 conjugated with phycoerythrin  (Miltenyi Biotec)
96
Miltenyi Biotec anti glast 1 conjugated with phycoerythrin
Anti Glast 1 Conjugated With Phycoerythrin, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti glast 1 conjugated with phycoerythrin/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
anti glast 1 conjugated with phycoerythrin - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
glast creer  (Jackson Laboratory)
86
Jackson Laboratory glast creer
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Glast Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glast creer/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
glast creer - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
apc  (Miltenyi Biotec)
96
Miltenyi Biotec apc
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
apc - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
glast acsa 1 antibody  (Miltenyi Biotec)
96
Miltenyi Biotec glast acsa 1 antibody
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Glast Acsa 1 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glast acsa 1 antibody/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
glast acsa 1 antibody - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
biotinylated antibody  (Miltenyi Biotec)
96
Miltenyi Biotec biotinylated antibody
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Biotinylated Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated antibody/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
biotinylated antibody - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
mouse anti human glutamine aspartate transporter  (Miltenyi Biotec)
96
Miltenyi Biotec mouse anti human glutamine aspartate transporter
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Mouse Anti Human Glutamine Aspartate Transporter, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human glutamine aspartate transporter/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
mouse anti human glutamine aspartate transporter - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
mouse glast creert  (Jackson Laboratory)
86
Jackson Laboratory mouse glast creert
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Mouse Glast Creert, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse glast creert/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
mouse glast creert - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
glast creert  (Jackson Laboratory)
86
Jackson Laboratory glast creert
VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
Glast Creert, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glast creert/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
glast creert - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::Ai14 mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.

Journal: Frontiers in Oncology

Article Title: Glia-derived VCAM1 promotes glioma progression

doi: 10.3389/fonc.2026.1802953

Figure Lengend Snippet: VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::Ai14 mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.

Article Snippet: C57BL/6J (stock#000664), Ai14 line (stock #007914), GLAST-CreER line(stock#012586), VCAM1 fl/fl (stock#007665) were purchased from Jackson Laboratory.

Techniques: Immunofluorescence, Staining

Knockout of VCAM1 in GLAST+ cells prolongs mouse survival. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::VCAM1 fl/fl and control mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week waiting period. On day 1, 5,000-6,000 tumor cells were injected into the cortex or below the hippocampus. Live imaging analysis was conducted at the predetermined points. (B) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells below the hippocampus. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, “ns” indicates no statistical significance ( p > 0.05). Here, p = 0.1209. (C) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells in the cortex. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, ** p = 0.0053. (D) Live imaging analysis of GL261-luc-bearing mice in hippocampus GLAST-CreER::VCAM1 fl/fl and control groups at days 9, 28 and 50. (E) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells below the hippocampus. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0223. (F) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Hippocampus GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, ** p = 0.0082. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA. (G) Live imaging analysis of GL261-luc-bearing mice in cortex from the GLAST-CreER::VCAM1 fl/fl and control groups at days 20, 40, 60. (H) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells in the cortex. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0465. (I) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Cortex GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, * p = 0.0106. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA.

Journal: Frontiers in Oncology

Article Title: Glia-derived VCAM1 promotes glioma progression

doi: 10.3389/fonc.2026.1802953

Figure Lengend Snippet: Knockout of VCAM1 in GLAST+ cells prolongs mouse survival. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::VCAM1 fl/fl and control mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week waiting period. On day 1, 5,000-6,000 tumor cells were injected into the cortex or below the hippocampus. Live imaging analysis was conducted at the predetermined points. (B) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells below the hippocampus. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, “ns” indicates no statistical significance ( p > 0.05). Here, p = 0.1209. (C) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells in the cortex. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, ** p = 0.0053. (D) Live imaging analysis of GL261-luc-bearing mice in hippocampus GLAST-CreER::VCAM1 fl/fl and control groups at days 9, 28 and 50. (E) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells below the hippocampus. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0223. (F) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Hippocampus GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, ** p = 0.0082. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA. (G) Live imaging analysis of GL261-luc-bearing mice in cortex from the GLAST-CreER::VCAM1 fl/fl and control groups at days 20, 40, 60. (H) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells in the cortex. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0465. (I) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Cortex GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, * p = 0.0106. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA.

Article Snippet: C57BL/6J (stock#000664), Ai14 line (stock #007914), GLAST-CreER line(stock#012586), VCAM1 fl/fl (stock#007665) were purchased from Jackson Laboratory.

Techniques: Knock-Out, Control, Injection, Imaging